Nutraceutical Product for Psoriasis: Advitech Solutions and French Company Pierre Jouan Biotechnologie Sign an Exclusive License Agreement

Quebec, June 9, 2003. – Advitech Solutions announces today that it has entered into an exclusive agreement with Pierre Jouan Biotechnologie SA. This agreement gives Advitech exclusive rights to the technology that the French company has developed for its applications for the treatment of psoriasis and other similar immune system disorders. This exclusive agreement covers, among others, the North American and Japanese markets.

The French technology is based on the activity of bioactive peptides obtained from an enriched whey protein fraction and uses a patented (pending) process. Advitech will apply this technology to its program for the development of a nutraceutical solution for psoriasis.
Psoriasis is a chronic inflammation of the skin which occurs in varying degrees of severity. Most research to date concludes that the disease results from an immune system disorder. In fact, it is often termed an autoimmune disorder. More than 6 million adults in the United States are affected by this skin disease.

The market for psoriasis treatment is expected to reach $1 billion US in 2007 according to several sources. Recent studies have shown that new products based on a better understanding of the immune system as it relates to psoriasis have the best chance of providing a major breakthrough in the treatment of this disease.

Advitech Solutions plans to begin clinical trials before the end of this year with its own XP-828 compound and depending on the success of these trials, to start marketing at the end of 2004.

"We are very excited about this agreement," says Mr Renaud Beauchesne, President and CEO of Advitech Solutions. “We feel that nutraceutical products based on bioactive peptides have a significant advantage over conventional approaches to treating psoriasis, which often produce serious side effects in patients”.

"This agreement regarding our technology represents an important step for our company. Advitech is recognized for its expertise in the field of bioactive peptides derived from milk proteins. We believe that by combining our technology with Advitech’s expertise, we will be able to provide psoriasis patients with a unique approach to what is a very complex disease,” announced Mr Benoît Jouan, President of Jouan Biotechnologie.

About Advitech Solutions

Advitech Solutions is a Canadian nutratech company involved in the research, development and marketing of nutraceutical products. Its interests are in the fields of immunology, inflammatory processes and stress management. Advitech is a recognized leader in the area of bioactive peptides derived from milk proteins. Its products are marketed under the Biozen and Prozen brand names. The company has more than 50 employees, with nearly a third of its staff engaged in research and development activities at its facility at l’Université Laval in Quebec City.

About Jouan Biotechnologie SA

Pierre Jouan Biotechnologie is a French biotech research and development company. Its aim is to define the physiological effects of lactopeptides and lactoproteins and to design industrial processes by which to isolate them for therapeutic use. The company develops and markets nutraceutical health products. In 2001, Pierre Jouan Biotechnologie received recognition from the French Ministry of Research and Industry for its research on psoriasis: the award for creation of an innovative technology company.

– 30 –

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.